Related Experiment Videos
Clopidogrel therapy--implications for hip fracture surgery
Antony Johansen1, James White, Adrian Turk
1Trauma Unit, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK. antony.johansen@cardiffandvale.wales.nhs.uk
Insights
Delaying hip fracture surgery for patients on clopidogrel may reduce blood loss but could increase risks of thromboembolic complications. An individualized approach is recommended for managing these patients.
Area of Science:
- Orthopedic Surgery
- Cardiology
- Pharmacology
Background:
- Clopidogrel is an anti-platelet medication increasingly used in patients with cardiovascular conditions.
- Hip fracture surgery is common in elderly patients, many of whom may be on clopidogrel therapy.
- The optimal management of hip fracture in patients taking clopidogrel remains unclear.
Purpose of the Study:
- To investigate the implications of clopidogrel therapy on peri-operative blood loss and complications in hip fracture patients.
- To evaluate the outcomes of delaying hip fracture surgery in patients taking clopidogrel.
Main Methods:
- Retrospective follow-up of 740 consecutive hip fracture admissions.
- Analysis of blood loss (hemoglobin fall) and complications in 17 patients on clopidogrel.
- Comparison of outcomes between patients with delayed surgery (≥5 days) and those without delay.
Main Results:
- A peri-operative fall in hemoglobin was 1.3g/dl less in patients whose surgery was delayed by at least 5 days (10 patients).
- The group with delayed surgery experienced potentially attributable thromboembolic complications.
- Clopidogrel therapy impacts peri-operative blood loss in hip fracture patients.
Conclusions:
- Clopidogrel therapy has implications for peri-operative blood loss in hip fracture surgery.
- Delaying surgery may reduce blood loss but carries a risk of thromboembolic complications.
- An individualized approach is recommended for managing hip fracture patients on clopidogrel therapy.
Abstract:
It remains unclear whether it is justifiable to delay hip fracture surgery in patients who are taking clopidogrel therapy-to allow the drug's anti-platelet effect to wear off. In a follow-up of 740 consecutive admissions with hip fracture we describe the extent of blood loss and complications in 17 (2.3%) who were taking clopidogrel. The peri-operative fall in haemoglobin was 1.3g/dl (95% CI: 0.4-2.3g/dl) less in the 10 patients in whom the surgeon's policy was for surgery to be delayed for at least 5 days. However, this group also experienced thromboembolic complications that were potentially attributable to this approach. Clopidogrel therapy does have implications for peri-operative blood loss, but hip fracture is a complex and multifactorial condition. We propose an individualised approach to patients taking this increasingly common drug.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis IV: Nursing Management